Valentina Cesario
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Valentina Cesario has a total of 109 co-authors. Here are the top co-authors by number of shared publications:
- Antonio Gasbarrini
Department of Internal Medicine and Gastroenterology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy
20 shared publications - Mariachiara Campanale
Digestive Endoscopy Unit, Fondazione Policlinico Universitario A. Gemelli, Rome, Italy
15 shared publications Giovanni Gigante
12 shared publications- Federico Barbaro
Institute of Internal Medicine and Gastroenterology, "A. Gemelli" Hospital, Catholic University, Rome, Italy.
11 shared publications Anna Maria De Gaetano
Department of Bioimaging and Radiological Sciences, Institute of Radiology, "A. Gemelli" Hospital - Catholic University, Rome, Italy; Division of Medical Oncology, "A. Gemelli" Hospital - Catholic University, Rome, Italy
10 shared publicationsMassimo Siciliano
Department of Internal Medicine, "A. Gemelli" Hospital - Catholic University, Rome, Italy; Division of Medical Oncology, "A. Gemelli" Hospital - Catholic University, Rome, Italy
10 shared publications
Latest Publications
- Open Access
- 1 January 2017
- Published by Elmer Press, Inc. in Journal of Clinical Medicine Research
- Vol. 9 (12) , 1022-1025
A Case of Moderate Sprue-Like Enteropathy Associated With Telmisartan
Sprue-like enteropathy associated with olmesartan medoxomil use has been recently reported. Its clinical manifestations include diarrhea, weight loss and malabsorption. Duodenal biopsies show villous atrophy (VA) with or without intraepithelial lymphocytosis and inflammation of the lamina propria. Serology for celiac disease (CD) is negative and gluten-free diet does not result in clinical improvement. Symptoms resolve after olmesartan discontinuation. Follow-up biopsies show recovery/improvement of the duodenum. Whether sprue-like enteropathy is a specific adverse reaction to olmesartan or rather a class effect of angiotensin-receptor blockers (ARBs) remains a controversial issue. We report a case of sprue-like enteropathy associated with telmisartan. A 52-year-old man presented with chronic diarrhea, abdominal discomfort and significant weight loss. In the last 3 years, he had been treated with telmisartan 40 mg/day for hypertension after right adrenalectomy for an aldosterone-producing adenoma. Laboratory investigations showed no significant abnormalities: Hb 13.6 g/dL, serum albumin 3.9 g/dL, total cholesterol 193 mg/dL, serum creatinine 0.99 mg/dL, sodium 143.6 mmol/L, K+ 4.3 mmol/L, calcium 9.3 mg/dL, phosphorus 3.9 mg/dL and 25-OH-D3 27.7 ng/mL. Duodenal histology showed subtotal VA and inflammation of the lamina propria. CD serology was negative. HLA-DQ typing showed absence of the DQ2/DQ8 haplotypes. After telmisartan discontinuation, patient's symptoms subsided, and his body weight increased despite persistence of a gluten-containing diet. Follow-up biopsies at 3 showed progressive duodenal recovery. Very few cases of sprue-like enteropathy associated with ARBs other than olmesartan have been reported. Our case of telmisartan-associated enteropathy further suggests that sprue-like disease may be a class effect of ARBs.
- 1 January 2017
- Published by Elmer Press, Inc. in Journal of Clinical Medicine Research
- Vol. 9 (12) , 1022-1025
Open AccessA Case of Moderate Sprue-Like Enteropathy Associated With Telmisartan
Sprue-like enteropathy associated with olmesartan medoxomil use has been recently reported. Its clinical manifestations include diarrhea, weight loss and malabsorption. Duodenal biopsies show villous atrophy (VA) with or without intraepithelial lymphocytosis and inflammation of the lamina propria. Serology for celiac disease (CD) is negative and gluten-free diet does not result in clinical improvement. Symptoms resolve after olmesartan discontinuation. Follow-up biopsies show recovery/improvement of the duodenum. Whether sprue-like enteropathy is a specific adverse reaction to olmesartan or rather a class effect of angiotensin-receptor blockers (ARBs) remains a controversial issue. We report a case of sprue-like enteropathy associated with telmisartan. A 52-year-old man presented with chronic diarrhea, abdominal discomfort and significant weight loss. In the last 3 years, he had been treated with telmisartan 40 mg/day for hypertension after right adrenalectomy for an aldosterone-producing adenoma. Laboratory investigations showed no significant abnormalities: Hb 13.6 g/dL, serum albumin 3.9 g/dL, total cholesterol 193 mg/dL, serum creatinine 0.99 mg/dL, sodium 143.6 mmol/L, K+ 4.3 mmol/L, calcium 9.3 mg/dL, phosphorus 3.9 mg/dL and 25-OH-D3 27.7 ng/mL. Duodenal histology showed subtotal VA and inflammation of the lamina propria. CD serology was negative. HLA-DQ typing showed absence of the DQ2/DQ8 haplotypes. After telmisartan discontinuation, patient's symptoms subsided, and his body weight increased despite persistence of a gluten-containing diet. Follow-up biopsies at 3 showed progressive duodenal recovery. Very few cases of sprue-like enteropathy associated with ARBs other than olmesartan have been reported. Our case of telmisartan-associated enteropathy further suggests that sprue-like disease may be a class effect of ARBs.
- 1 February 2016
- Published by Elsevier in Digestive and Liver Disease
- Vol. 48 (2) , 182-188
Percutaneous real-time sonoelastography as a non-invasive tool for the characterization of solid focal liver lesions: A prospective study
- 1 February 2016
- Published by Elsevier in Digestive and Liver Disease
- Vol. 48 (2) , 182-188
Percutaneous real-time sonoelastography as a non-invasive tool for the characterization of solid focal liver lesions: A prospective study
- 1 March 2015
- Published by Elsevier in Digestive and Liver Disease
- Vol. 47 (3) , 242-248
Radiofrequency ablation plus drug-eluting beads transcatheter arterial chemoembolization for the treatment of single large hepatocellular carcinoma
- 1 March 2015
- Published by Elsevier in Digestive and Liver Disease
- Vol. 47 (3) , 242-248
Radiofrequency ablation plus drug-eluting beads transcatheter arterial chemoembolization for the treatment of single large hepatocellular carcinoma
- 1 May 2013
- Published by Elsevier in Gastroenterology
- Vol. 144 (5)
Mo2030 Treatment of Portal Vein Tumor Thrombosis (PVTT) Can Impact Survival of Patients With Advanced HCC?
- 1 May 2013
- Published by Elsevier in Gastroenterology
- Vol. 144 (5)
Mo2030 Treatment of Portal Vein Tumor Thrombosis (PVTT) Can Impact Survival of Patients With Advanced HCC?
- 1 May 2013
- Published by Elsevier in Gastroenterology
- Vol. 144 (5)
Mo2028 Comparison Between Transcatheter Arterial Chemoembolization (TACE) and Transcatheter Arterial Chemoembolization Combined With Percutaneous Radiofrequency Ablation (TACE-RFA) for Treatment of Intermediate Hepatocellular Carcinoma
- 1 May 2013
- Published by Elsevier in Gastroenterology
- Vol. 144 (5)
Mo2028 Comparison Between Transcatheter Arterial Chemoembolization (TACE) and Transcatheter Arterial Chemoembolization Combined With Percutaneous Radiofrequency Ablation (TACE-RFA) for Treatment of Intermediate Hepatocellular Carcinoma
- 1 May 2013
- Published by Elsevier in Gastroenterology
- Vol. 144 (5)
Su2021 Early PEAK of Hydrogen During Lactose Breath Test Predict Intestinal Motility
- 1 May 2013
- Published by Elsevier in Gastroenterology
- Vol. 144 (5)
Su2021 Early PEAK of Hydrogen During Lactose Breath Test Predict Intestinal Motility
- 1 May 2012
- Published by Elsevier in Gastroenterology
- Vol. 142 (5)
Sa1422 Efficacy of Amytriptiline in Improving Intestinal Permeability and Quality of Life in Patients With IBS
- 1 May 2012
- Published by Elsevier in Gastroenterology
- Vol. 142 (5)
Sa1422 Efficacy of Amytriptiline in Improving Intestinal Permeability and Quality of Life in Patients With IBS